Biopharma News

Sep 08, 2017
By BioPharm International Editors
The pharma major anticipates an annualized cost savings of roughly $500 million starting in 2018 based on a significant reduction in its global workforce.
Sep 07, 2017
By BioPharm International Editors
Roche’s subsidiary, Genentech, issued the voluntary recall of the anti-stroke drug because of compromised vials containing sterile water that were packaged with the drug.
Sep 07, 2017
By BioPharm International Editors
With this acquisition, Merck gains a lead anti-tumor drug candidate and a proprietary technology that can potentially induce immediate and long-term anti-tumor immunity.
Sep 07, 2017
By BioPharm International Editors
Merck KGaA completes the divestment of its biosimilars business as part of its strategy to focus on developing a pipeline of innovator drugs.
Sep 07, 2017
By BioPharm International Editors
As Merck KGaA continues its strategic shift into a science and technology company, it is considering options for its Consumer Health business, including a potential sale.
Sep 06, 2017
By BioPharm International Editors
Pfizer’s Mylotarg, an anti-body drug conjugate once voluntarily withdrawn, returns to the market under a new dosing regimen for treating leukemia.
Sep 05, 2017
By BioPharm International Editors
Novartis has appointed Dr. Vasant Narasimhan as CEO.
Sep 01, 2017
By BioPharm International Editors
With this acquisition, Oncurious, a Belgium-based biotechnology company, will gain a pipeline of immune-oncology drug candidates.
Sep 01, 2017
By BioPharm International Editors
Bristol-Myers Squibb (BMS) and Daiichi Sankyo announced a collaboration to evaluate the combination of Opdivo (nivolumab) and antibody drug conjugate (ADC) DS-8201 for treating breast and bladder cancers.
Aug 31, 2017
By BioPharm International Editors
MilliporeSigma announced a collaboration with Angiex, a biotechnology start-up, to support the development of Angiex’s lead oncology antibody drug candidate to clinical use.
native1_300x100
lorem ipsum